New Paradigms in Hypertrophic Cardiomyopathy Care Gameshow Challenge: Cardiac Myosin Inhibition

Despite the relatively high prevalence of hypertrophic cardiomyopathy (HCM), reported to be as high as 1 in 200 individuals, most individuals are undiagnosed and untreated. The pathophysiology of HCM is complex and consists of multiple interrelated abnormalities. In order to move the needle from an often-fatal condition to a treatable chronic condition, clinicians must be able to identify patients, understand the challenges of diagnosis, and implement new and emerging treatment options for their patient. 
 
What is the underlying pathophysiology of HCM? How do you diagnose a patient with HCM? Are you treating patients according to current HCM guideline recommendations? What about cardiac myosin inhibitors – where do they fit into the treatment algorithm for HCM? 
 
Join our panel of leading experts for a unique and interactive gameshow-style educational symposium on HCM to get the answers to all these questions, and guide your team to victory!

An accredited satellite program, provided by Medscape and supported through an independent educational grant from Cytokinetics